It is with hope that an increased number of immune checkpoints (such as CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT) be documented, although some tumor patients show immunotherapy tolerance (42–44). This evidence concerns the gene HAVCR2 and neoplasm.